Global Melanoma Treatment Market Poised to Surpass $12 Billion by 2028, Driven by Advances in Immunotherapy and Targeted Therapies - ResearchAndMarkets.com

2023-12-20

免疫疗法

DUBLIN--(BUSINESS WIRE)--The "Melanoma Therapeutics Melanoma Therapeutics: Global Markets" report has been added to ResearchAndMarkets.com's offering.

The global market for melanoma treatment was estimated to reach $6.8 billion in 2022 and is expected to reach $12.1 billion through 2028, growing at a CAGR of 10.2% during the forecast period.

Major players in the market include Merck & Co., Bristol Myers Squibb and Novartis. Apart from the major players there are also small biotech companies such as Erasca, HUYABIO International and IO Biotech that have promising drug candidates in the pipeline, which should push market growth during the forecast period.

Growth Drivers:

The analysis disclosed in this publication stresses the instrumental role of modern medical interventions, such as the introduction of immune-checkpoint inhibitors and small molecule-targeted therapies, in revolutionizing the treatment landscape for advanced melanoma. With a compound annual growth rate (CAGR) of 10.2% projected from 2022 through 2028, the melanoma treatment sector is witnessing an uptrend, underpinned by increasing drug approvals and surging patient survival rates. Biotechnological innovations and strategic initiatives by industry leaders compound the market expansion.

Regional Insights:

The North American melanoma treatment sector emerges as the frontrunner, closely trailed by Europe, accounting for the lion's share of the global market. Factors spurring growth in these regions include heightened healthcare expenditure, public awareness campaigns, and supportive government frameworks. In particular, immunotherapies dominate the therapeutics segment, claiming the majority market share in 2022.

Vital Segmentation:

The research delves into the segmentation of the melanoma treatment market by treatment type, cancer stage, and therapeutics. The localized stage of melanoma garners considerable attention due to the high success rates of surgical interventions, which remain the primary treatment approach.

Pipeline Analysis:

With a spotlight on the promising treatment pipeline, the publication highlights the continuous emergence of first-in-class molecules targeting novel aspects of melanoma. A burgeoning focus on personalized medicine, epitomized through innovative cell therapies and vaccines, showcases a commitment to tackling disease recurrence and improving patient outcomes.

Market Dynamics:

The report articulates the dual forces shaping the melanoma treatment marketplace, identifying critical stimulants such as technological progressions, enhanced detection tools, and patient advocacy. Conversely, challenges like the high costs of cutting-edge treatments and regulatory hurdles are acknowledged as potential market constraints.

Key Players:

Spotlighting the change-makers, the research profiles leading organizations and emerging biotech firms that are catalyzing paradigm shifts in melanoma therapeutics. These entities are pioneering the development of groundbreaking treatments, consequently fortifying their market position.

The report profiles the following leading players

Erasca

Huyabio International

Iovance Biotherapeutics

Moderna Ina.

Regeneron Pharmaceuticals

Key Attributes:

Report Attribute

Details

No. of Pages

131

Forecast Period

2023 - 2028

Estimated Market Value (USD) in 2023

$7.4 Billion

Forecasted Market Value (USD) by 2028

$12.1 Billion

Compound Annual Growth Rate

10.2%

Regions Covered

Global

Key Topics Covered:

Chapter 1: Introduction

Chapter 2: Summary and Highlights

Chapter 3: Market and Technology Background

Risk Factors, Causes and Prevention

Symptoms

Pathophysiology and Clinical Subtypes

Prognosis

Epidemiology

Diagnosis

Biopsy

Laboratory Tests

Blood Tests

Imaging Tests

Treatment

Immunotherapy

PD-1 and PD-L1 Inhibitors PD-L1 Inhibitors

CTLA-4 inhibitors CTLA-4 inhibitors

LAG-3 Inhibitors LAG-3 Inhibitors

Interleukin-2 (IL-2, Proleukin)

Virus Therapy

BRAF inhibitors:

MEK Inhibitors

Chapter 4: Market Dynamics

Market Factors

Market Drivers

Increasing Prevalence of Melanoma

Technological Advancements and Product Launches

Strategic Initiatives

Developments in Early Detection Tools

Patient Advocacy Groups and Awareness

Market Restraints

High Cost of Treatment

Stringent Regulations

Resistance to Therapies

Market Opportunities

Chapter 5: Market Breakdown by Type

Surgery

Wide Excision

Mohs Surgery

Amputation

Lymph Node Dissection

Therapeutics

Therapeutics by Type

Radiation Therapy

Chapter 6: Market Breakdown by Disease Stage

Localized Disease

Regional Disease

Distant Disease

Chapter 7: Market Breakdown by Region

Chapter 8: Sustainability: An ESG Perspective

ESG Challenges in the Pharmaceutical Industry

ESG Practices in the Market for Melanoma Therapeutics

Case Study

Research Viewpoint

Chapter 9: Emerging Technologies/ Developments

Novel Immune Checkpoint Inhibitors Immune Checkpoint Inhibitors Immune Checkpoint Inhibitors

Adoptive Cell Therapy

Engineered TCR Therapy

Vaccines

Targeted Therapy

Chapter 10: Regulatory Landscape and Pipeline Analysis

Chapter 11: Patent Analysis

Chapter 12: Competitive Landscape

Chapter 13: Company Profiles

For more information about this report visit https://www.researchandmarkets.com/r/i3kz5h

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.